I think there’s a lot of exciting things to come within kidney cancer specifically. We’re going to have longer term follow up of some key data, pembrolizumab in the adjuvant setting. We’re going to hear about some novel agents as well, a newer TKI, savolitinib, a new update today that ARCC20, but also exciting data on new HIF-2 alpha inhibitors like belzutifan...
I think there’s a lot of exciting things to come within kidney cancer specifically. We’re going to have longer term follow up of some key data, pembrolizumab in the adjuvant setting. We’re going to hear about some novel agents as well, a newer TKI, savolitinib, a new update today that ARCC20, but also exciting data on new HIF-2 alpha inhibitors like belzutifan. So I think there’s going to be a wide range of both sort of updates of really practice changing studies, but also newer agents that’s hopefully going to change practice in the coming years.
